Transient reperfusion with acidic solution affects postischemic functional recovery: studies in the isolated working rat heart. 1996

T Ohashi, and F Yamamoto, and H Yamamoto, and H Ichikawa, and T Shibata, and Y Kawashima
Department of Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan.

This isolated working rat heart study was designed to investigate the effect of duration of reperfusion and degree of acidity of the reperfusate on myocardial protection. The experimental time course was as follows: 20 minutes of perfusion with the heart working, 3 minutes of infusion with the St. Thomas' Hospital cardioplegic solution followed by global ischemia for 33 minutes at 37 degrees C, and 20 minutes of Langendorff reperfusion followed by 20 minutes of working perfusion. During the initial 3 minutes of Langendorff reperfusion, the pH of the reperfusate was changed to 5.6, 6.8, and 7.5 by addition of sodium hydroxide into Krebs-Henseleit nonbicarbonate HEPES buffer. A respiratory acidic reperfusate was used for the initial 0.5, 1, 2, 3, 5, and 15 minutes during reperfusion. The results were as follows: (1) Reperfusion with a mildly acidic solution (i.e., pH 6.8) yielded better recovery than reperfusion with solutions having pH levels of 5.8 or 7.5. (2) Reperfusion for less than 3 minutes with a reperfusate having a pH level of 6.8 provided better recovery, although reperfusion for longer than 3 minutes exacerbated reperfusion injury. In conclusion, the effects of reperfusion with acidic solution were influenced by degree and duration with biphasic response characteristics.

UI MeSH Term Description Entries
D008297 Male Males
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014325 Tromethamine An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424) Tris Buffer,Trisamine,Trometamol,Tri(hydroxymethyl)aminomethane,Tris(hydroxymethyl)aminomethane,Tris-Magnesium(II)-Potassium Chloride Buffer,Tris-Mg(II)-KCl Buffer,Trizma
D015425 Myocardial Reperfusion Generally, restoration of blood supply to heart tissue which is ischemic due to decrease in normal blood supply. The decrease may result from any source including atherosclerotic obstruction, narrowing of the artery, or surgical clamping. Reperfusion can be induced to treat ischemia. Methods include chemical dissolution of an occluding thrombus, administration of vasodilator drugs, angioplasty, catheterization, and artery bypass graft surgery. However, it is thought that reperfusion can itself further damage the ischemic tissue, causing MYOCARDIAL REPERFUSION INJURY. Coronary Reperfusion,Reperfusion, Myocardial,Coronary Reperfusions,Myocardial Reperfusions,Reperfusion, Coronary,Reperfusions, Coronary,Reperfusions, Myocardial
D015428 Myocardial Reperfusion Injury Damage to the MYOCARDIUM resulting from MYOCARDIAL REPERFUSION (restoration of blood flow to ischemic areas of the HEART.) Reperfusion takes place when there is spontaneous thrombolysis, THROMBOLYTIC THERAPY, collateral flow from other coronary vascular beds, or reversal of vasospasm. Reperfusion Injury, Myocardial,Injury, Myocardial Reperfusion,Myocardial Ischemic Reperfusion Injury,Injuries, Myocardial Reperfusion,Myocardial Reperfusion Injuries,Reperfusion Injuries, Myocardial

Related Publications

T Ohashi, and F Yamamoto, and H Yamamoto, and H Ichikawa, and T Shibata, and Y Kawashima
September 1990, The American journal of physiology,
T Ohashi, and F Yamamoto, and H Yamamoto, and H Ichikawa, and T Shibata, and Y Kawashima
July 2013, The Journal of surgical research,
T Ohashi, and F Yamamoto, and H Yamamoto, and H Ichikawa, and T Shibata, and Y Kawashima
January 1985, Anesthesiology,
T Ohashi, and F Yamamoto, and H Yamamoto, and H Ichikawa, and T Shibata, and Y Kawashima
August 1992, The Journal of thoracic and cardiovascular surgery,
T Ohashi, and F Yamamoto, and H Yamamoto, and H Ichikawa, and T Shibata, and Y Kawashima
May 2003, Molecular and cellular biochemistry,
T Ohashi, and F Yamamoto, and H Yamamoto, and H Ichikawa, and T Shibata, and Y Kawashima
March 1991, Journal of cardiovascular pharmacology,
T Ohashi, and F Yamamoto, and H Yamamoto, and H Ichikawa, and T Shibata, and Y Kawashima
August 1993, Biochemical medicine and metabolic biology,
T Ohashi, and F Yamamoto, and H Yamamoto, and H Ichikawa, and T Shibata, and Y Kawashima
January 1991, Arkhiv patologii,
T Ohashi, and F Yamamoto, and H Yamamoto, and H Ichikawa, and T Shibata, and Y Kawashima
December 2004, American journal of physiology. Heart and circulatory physiology,
T Ohashi, and F Yamamoto, and H Yamamoto, and H Ichikawa, and T Shibata, and Y Kawashima
June 2001, Journal of hypertension,
Copied contents to your clipboard!